Cargando…
Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?
In resectable colorectal liver metastasis (CRLM) the role and use of molecular biomarkers is still controversial. Several biomarkers have been linked to clinical outcomes in CRLM, but none have so far become routine for clinical decision making. For several reasons, the clinical risk score appears t...
Autores principales: | Veen, Torhild, Søreide, Kjetil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348630/ https://www.ncbi.nlm.nih.gov/pubmed/28344745 http://dx.doi.org/10.4251/wjgo.v9.i3.98 |
Ejemplares similares
-
KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?
por: Søreide, Kjetil, et al.
Publicado: (2014) -
Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment
por: Zaharia, Claudia, et al.
Publicado: (2022) -
Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?
por: Søreide, Kjetil
Publicado: (2021) -
Resection of asymptomatic primary tumour in unresectable stage IV colorectal cancer: time to move on from propensity matched scores to randomized controlled trials
por: Søreide, Kjetil
Publicado: (2016) -
Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis
por: Søreide, Kjetil, et al.
Publicado: (2016)